Category News

Elevance Health Addresses Healthcare’s Digital Divide by Increasing Access to High-Quality Smartphones and Health-Related Digital Services

Elevance Health gives eligible consumers no-cost access to customized suite of digital and virtual health tools through funding from the Affordable Connectivity Program Elevance Health announced at the Consumer Electronics…

Read MoreElevance Health Addresses Healthcare’s Digital Divide by Increasing Access to High-Quality Smartphones and Health-Related Digital Services

Henry Schein Medical Introduces the Henry Schein ‘RISE’ Platform for Ambulatory Surgery Centers

 Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), today announced the launch of Henry Schein RISE (Resources, Infection Prevention, Solutions & Support, Education) – a platform designed to provide ambulatory surgery…

Read MoreHenry Schein Medical Introduces the Henry Schein ‘RISE’ Platform for Ambulatory Surgery Centers

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Delaware Court of Chancery (the “Court”) ruled that the nomination notice (the “Notice”) submitted by a member…

Read MoreDelaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034 – Shaping the Future of Rare Disease Treatment with Viral Vector Solutions

The “Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034” report has been added to ResearchAndMarkets.com’s offering. Overall world revenue for the viral vectors and plasmid DNA manufacturing market is forecast to surpass US$1.35…

Read MoreViral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034 – Shaping the Future of Rare Disease Treatment with Viral Vector Solutions

QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay

 Quidel Corporation (NASDAQ: QDEL), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received 510(K) clearance from the U.S. Food…

Read MoreQuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay

World Courier to Expand Storage Capacity and Cold Chain Capabilities With Three New Transport Stations in the United States

World Courier, a global specialty logistics provider and a part of Cencora (formerly AmerisourceBergen), will open transport stations in three new markets in the United States, expanding its presence and capacity to…

Read MoreWorld Courier to Expand Storage Capacity and Cold Chain Capabilities With Three New Transport Stations in the United States

Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and…

Read MoreGenentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage…

Read MoreGenentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment